ES2638072T3 - Método de cristalización y biodisponibilidad - Google Patents

Método de cristalización y biodisponibilidad Download PDF

Info

Publication number
ES2638072T3
ES2638072T3 ES11740284.2T ES11740284T ES2638072T3 ES 2638072 T3 ES2638072 T3 ES 2638072T3 ES 11740284 T ES11740284 T ES 11740284T ES 2638072 T3 ES2638072 T3 ES 2638072T3
Authority
ES
Spain
Prior art keywords
lysine
glycine
another embodiment
acid
zoledronic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11740284.2T
Other languages
English (en)
Spanish (es)
Inventor
Mazen Hanna
Ning SHAN
Miranda L. Cheney
David R. Weyna
Raymond Houck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grünenthal GmbH
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/847,568 external-priority patent/US8399023B2/en
Priority claimed from PCT/US2010/043916 external-priority patent/WO2011014781A1/en
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Application granted granted Critical
Publication of ES2638072T3 publication Critical patent/ES2638072T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES11740284.2T 2010-02-06 2011-02-02 Método de cristalización y biodisponibilidad Active ES2638072T3 (es)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US847568 1997-04-24
US312879P 2001-08-16
US333041P 2001-11-16
US359544P 2002-02-25
US30211010P 2010-02-06 2010-02-06
US302110P 2010-02-06
US31287910P 2010-03-11 2010-03-11
US31850310P 2010-03-29 2010-03-29
US318503P 2010-03-29
US33302810P 2010-05-10 2010-05-10
US33304110P 2010-05-10 2010-05-10
US333028P 2010-05-10
US35954410P 2010-06-29 2010-06-29
WOPCT/US2010/043892 2010-07-30
WOPCT/US2010/043916 2010-07-30
US12/847,568 US8399023B2 (en) 2009-07-31 2010-07-30 Crystallization method and bioavailability
PCT/US2010/043892 WO2011014766A2 (en) 2009-07-31 2010-07-30 Crystallization method and bioavailability
PCT/US2010/043916 WO2011014781A1 (en) 2009-07-31 2010-07-30 Novel oral forms of a phosphonic acid derivative
US37981410P 2010-09-03 2010-09-03
US379814P 2010-09-03
US45577810P 2010-10-26 2010-10-26
US455778P 2010-10-26
PCT/US2011/023427 WO2011097269A1 (en) 2010-02-06 2011-02-02 Crystallization method and bioavailability

Publications (1)

Publication Number Publication Date
ES2638072T3 true ES2638072T3 (es) 2017-10-18

Family

ID=44355747

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11740284.2T Active ES2638072T3 (es) 2010-02-06 2011-02-02 Método de cristalización y biodisponibilidad

Country Status (15)

Country Link
EP (1) EP2531200B1 (enExample)
JP (2) JP5792748B2 (enExample)
AU (2) AU2012216632B2 (enExample)
CA (1) CA2826548A1 (enExample)
CY (1) CY1119192T1 (enExample)
DK (1) DK2531200T3 (enExample)
ES (1) ES2638072T3 (enExample)
HR (1) HRP20171201T1 (enExample)
HU (1) HUE035744T2 (enExample)
IL (1) IL221306A0 (enExample)
LT (1) LT2531200T (enExample)
PL (1) PL2531200T3 (enExample)
PT (1) PT2531200T (enExample)
SI (1) SI2531200T1 (enExample)
WO (1) WO2011097269A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2011014781A1 (en) * 2009-07-31 2011-02-03 Thar Pharmaceuticals, Inc. Novel oral forms of a phosphonic acid derivative
KR101813728B1 (ko) 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
EP2531200B1 (en) * 2010-02-06 2017-07-12 Grünenthal GmbH Crystallization method and bioavailability
WO2012071517A2 (en) * 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
CN102268023B (zh) * 2011-08-15 2013-04-17 南京丰融化学技术有限公司 头孢类衍生物cxd的晶型
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US20140349974A1 (en) * 2014-08-12 2014-11-27 Antecip Bioventures Ii Llc Zoledronic acid dosage forms for the treatment of pain
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
PL2849758T3 (pl) * 2012-05-14 2018-08-31 Antecip Bioventures Ii Llc Kompozycje zawierające kwas zoledronowy lub pokrewne związki do uśmierzania bólu zapalnego i stanów powiązanych
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
EP2968371A4 (en) * 2013-03-12 2017-04-12 The Board of Trustees of the Leland Stanford Junior University Modulation of cellular dna repair activity to intercept malignancy
US11406713B2 (en) 2013-03-15 2022-08-09 Xortx Therapeutics, Inc. Xanthine oxidase inhibitor formulations
KR101739244B1 (ko) * 2013-10-25 2017-05-23 안테씨프 바이오벤쳐스 투 엘엘씨 질병의 치료를 위한, 졸레드론산 또는 관련 화합물의 경구 투여용 조성물
MX2018002627A (es) * 2015-09-18 2018-12-17 Gruenenthal Chemie Metodo de cristalizacion y biodisponibilidad.
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
KR102723076B1 (ko) * 2016-12-15 2024-11-28 제이투에이치바이오텍 (주) 3성분 코크리스탈
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
EP1416919A1 (en) 2001-07-17 2004-05-12 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
US20040220264A1 (en) * 2003-03-17 2004-11-04 Yu Ruey J Bioavailability and improved delivery of acidic pharmaceutical drugs
ES2322592T3 (es) * 2003-07-03 2009-06-23 Teva Pharmaceutical Industries Ltd. Formas cristalinas de acido zoledronico, formas cristlinas de la sal sodica de zoledronato, sal sodica de zoledronato amorfa y procedimientos para su preparacion.
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
WO2011014781A1 (en) * 2009-07-31 2011-02-03 Thar Pharmaceuticals, Inc. Novel oral forms of a phosphonic acid derivative
KR101813728B1 (ko) * 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
EP2531200B1 (en) * 2010-02-06 2017-07-12 Grünenthal GmbH Crystallization method and bioavailability
WO2012071517A2 (en) * 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
CN102070668B (zh) * 2010-12-23 2013-07-24 蚌埠丰原医药科技发展有限公司 一种利用相转移催化剂制备唑来膦酸及其钠盐的方法

Also Published As

Publication number Publication date
WO2011097269A1 (en) 2011-08-11
CA2826548A1 (en) 2011-08-11
JP6190429B2 (ja) 2017-08-30
HUE035744T2 (en) 2018-05-28
IL221306A0 (en) 2012-10-31
AU2016219653A1 (en) 2016-09-15
WO2011097269A9 (en) 2012-12-27
JP2016006096A (ja) 2016-01-14
AU2016219653B2 (en) 2018-05-31
DK2531200T3 (en) 2017-09-11
CY1119192T1 (el) 2018-02-14
AU2012216632B2 (en) 2016-05-26
JP5792748B2 (ja) 2015-10-14
JP2013519632A (ja) 2013-05-30
PT2531200T (pt) 2017-08-24
SI2531200T1 (sl) 2017-12-29
EP2531200A4 (en) 2014-01-08
HRP20171201T1 (hr) 2017-10-06
EP2531200B1 (en) 2017-07-12
PL2531200T3 (pl) 2017-10-31
LT2531200T (lt) 2017-09-25
EP2531200A1 (en) 2012-12-12

Similar Documents

Publication Publication Date Title
US9169279B2 (en) Crystallization method and bioavailability
ES2650665T3 (es) Método de cristalización y biodisponibilidad
EP2531200B1 (en) Crystallization method and bioavailability
US20190083407A1 (en) Crystallization method and bioavailability
US20140349974A1 (en) Zoledronic acid dosage forms for the treatment of pain
ES2329971T3 (es) Composicion farmaceutica para la liberacion controlada de paracetamol.
ES2197369T3 (es) Composiciones farmaceuticas para la liberacion sostenida de fluvastatina inhibidora de hmg-coa reductasa.
ES2610966T3 (es) Formulaciones que comprenden 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol
ES2641889T3 (es) Formulaciones de diclofenaco y métodos de uso
US10093691B2 (en) Crystallization method and bioavailability
ES2640816T3 (es) Utilización de una matriz para administración oral de magnesio de liberación prolongada y composición que contiene esta matriz
ES2297166T3 (es) Sales estables del acido o-acetilsalicilico con aminoacidos basicos ii.
ES2234051T3 (es) Composiciones farmaceuticas de cilansetron estabilizadas contra la racemizacion.
ES2770500T3 (es) Composición farmacéutica que comprende fingolimod
ES2229793T3 (es) Composiciones farmaceuticas que contienen quinapril magnesio.
ES2794917T3 (es) Forma cristalina II de clorhidrato de anagrelida monohidratado
US6794536B1 (en) Method for preparation of disodium pamidronate
WO2022119429A1 (es) Medicamento de combinación fija para el control y manejo del dolor neuropático
JP7646382B2 (ja) ヨウ化イソプロパミド含有医薬
PT1906931E (pt) Composição farmacêutica melhorada contendo um inibidor da ace e método para a sua preparação
JPH09255575A (ja) アセチルサリチル酸誘導体含有製剤
IE45201B1 (en) Solid choline salicylate compositions